Abuse Potential of Buprenorphine & Naloxone in Non-Dependent Opioid Users

Status Completed

Clinical Trial Summary

Buprenorphine is a medication used to treat opioid addiction, but individuals who use this drug are at risk of abusing it. A buprenorphine and naloxone combination may reduce the likelihood of buprenorphine addiction. This study will evaluate the potential for abuse of buprenorphine and a buprenorphine and naloxone combination in non-dependent opioid users.

Clinical Trial Description

Opioid withdrawal symptoms are a major contributing factor for why opioid treatment programs often fail. Individuals with severe opioid withdrawal may experience shaking, muscle and bone pain, nausea, depression, anxiety, and drug craving. Buprenorphine, a medication that is used to treat opioid addiction, works by lessening the withdrawal symptoms. However, past research has shown that individuals who use buprenorphine are at risk for abusing the drug. Naloxone, another medication, is currently used to treat substance addiction. It is also used in combination with buprenorphine to reduce the risk of buprenorphine abuse in individuals who are physically dependent upon opioids. The purpose of this study is to compare the abuse potential of buprenorphine versus a buprenorphine and naloxone combination in non-dependent opioid users.

This 7-week study will enroll non-dependent opioid users. Participants will take part in two medication challenge sessions per week. At each challenge session, participants will be randomly assigned to receive varying doses of either buprenorphine; a buprenorphine and naloxone combination; hydromorphone, which is a medication used to treat moderate to severe pain; or placebo. Buprenorphine and naloxone will be administered as tablets that are dissolved under the tongue. Hydromorphone will be injected. During the challenge sessions, participants will complete performance tasks to measure psychomotor and cognitive functioning. Questionnaires and self-reports will be completed to assess medication effects. Heart rate and blood pressure will be monitored throughout all sessions, and a specialized camera will be used to assess pupillary response of the eyes. ;

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Opioid-Related Disorders

Clinical Trial Details

NCT number	NCT00158236
Study type	Interventional
Source	National Institute on Drug Abuse (NIDA)
Contact
Status	Completed
Phase	N/A
Start date	January 1997
Completion date	March 1998

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03950492` - Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder	N/A
Completed	`NCT00000335` - Activity Monitoring Assessment of Opiate Withdrawal - 4	Phase 2
Active, not recruiting	`NCT03949764` - The Kentucky Viral Hepatitis Treatment Study	Phase 4
Enrolling by invitation	`NCT06084221` - Fatal Overdose Review Teams - Research to Enhance Surveillance Systems	N/A
Completed	`NCT02978417` - Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings	Phase 4
Withdrawn	`NCT03137030` - A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults	Phase 1
Withdrawn	`NCT03137017` - A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults	Phase 1
Completed	`NCT02282306` - Phone Interview to Prevent Recurring Opioid Overdoses	N/A
Completed	`NCT00710385` - Abuse Liability of Suboxone Versus Subutex	Phase 3
Completed	`NCT00142935` - Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1	N/A
Completed	`NCT00218309` - Effects of Pre-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals	Phase 2
Completed	`NCT00067184` - Fetal Neurobehavioral Development in Methadone Maintained Pregnancies
Terminated	`NCT00000243` - Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on Methadone	N/A
Completed	`NCT00000264` - Subjective/Psychomotor/ Effects of Combined Alcohol & Nitrous Oxide - 16	N/A
Completed	`NCT00000257` - Effects of Alcohol History on Effects of Nitrous Oxide - 9	N/A
Completed	`NCT00000306` - Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3	Phase 2
Completed	`NCT00000279` - Novel Medications for Opiate Detoxification - 4	Phase 2
Completed	`NCT00000249` - Effects of Subanesthetic Concentrations of Nitrous Oxide - 1	Phase 2
Recruiting	`NCT04933084` - Pre-operative Education Modalities to Decrease Opioid Use	N/A
Recruiting	`NCT03610672` - Mobile Intervention for Young Opioid Users	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Abuse Potential of Buprenorphine and Naloxone in Non-Dependent Opioid Users

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms